Abstract:Interferon-alpha (IFN-alpha) has been found to exert multiple enhancing effects in the immune response in vitro, IFN-alpha has been also used in clinical trials with variable response rates. The aim of the present study was to assess the effectiveness of IFN-alpha in the treatment of 25 patients with malignant pleural or peritoneal effusions caused by lung, and metastatic breast and ovarian cancer. Clinical responses were correlated with a) the ratio of malignant effusion (ME)-associated tumor cells to ME-associated mononuclear cells (MEMNC), b) MEMNC-derived cytotoxic responses against autologous or allogeneic tumor targets, and c) major histocompatibility complex (MHC) antigen expression on tumor cells. After partial drainage of pleural or peritoneal fluid, the patients were allocated to receive 10 million units of IFN-alpha by intrapleural or intraperitoneal injection at weekly intervals. The treatment was terminated if the malignant effusion disappeared or the patients had received four to six consecutive procedures. None of the patients received concomitant systemic chemotherapy or radiation therapy. MEMNC and tumor cells were isolated by centrifugation on discontinous percoll density gradients. Cytotoxic and phenotypic profiles of MEMNG were analyzed before and after treatment with IFN-alpha. An improvement was observed in patients with increased ratios of tumor cells to malignant effusion-associated mononuclear cells (MEMNC) in the effusions. In the same patients MEMNC were overpopulated by CD8+ T lymphocytes. In this group of patients the administration of IFN-alpha was associated with 25% complete response and 75% partial response rates. In contrast only 17% partial responses were achieved in patients whose effusions had decreased tumor cell to MEMNC ratios. The immunomodulation induced by IFN-alpha in vivo was also tested. Thus in a group of 6 patients, treatment with IFN-alpha resulted in the induction of CD8+ cell-mediated lysis against autologous tumor cells which was associated with PR (two patients). Natural killer (NK)-cell activity, and MHC class I antigen expression on effusion-associated tumor cells were also enhanced during treatment, but were not correlated with the outcome of the therapy since similar findings were also observed in the 4 non-responders. Local infusions of IFN-alpha provide an effective alternative treatment for malignant effusion in patients with lung, breast, and ovarian cancer. Increased ratios of tumor cells to MEMNC and the presence of CD8+ T lymphocytes within the malignant effusions may play an important role in the outcome of such a treatment with IFN-alpha but more patients need to be studied for definite conclusions.

Curative Effect of Local TNF Inoculation for Patients with Malignant Effusion

Prospective, multicenter clinical study of rmhTNF-NC injection in the treatment of Chinese malignant pleural effusion or peritoneal effusion patients

Multicenter phase Ⅱclinical trial of rhTNF-NC injection in the treatment of malignant tumors

Therapeutic Effect of Tumor Infiltrating Lymphocyte Plus Interleukin-2 Intrapleural Injection on Advanced Cancer Patients with Malignant Pleural Effusion

Intrathoracic Administration of Recombinant Human Tumor Necrosis Factor-alpha with Closed Small Tube Drainage for Malignant Pleural Effusions: a Phase Ⅲ Clinical Study

Clinical effects of recombinant mutant human tumor necrosis factor on the malignant pleural effusion in-duced by lung adenocarcinoma

Effects of intrapleural therapy on 96 patients with malignant pleural effusion

Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters

Treatment of Malignant Pleural Effusion with Radiofrequency Hyperthermia Combined with Intravenous Chemotherapy and Intrapleural Injection

Efficacy and Safety of Recombinant Human Tumor Necrosis Factor Application for the Treatment of Malignant Pleural Effusion Caused by Lung Cancer

The Clinical Study of the Change of HLA-DR, PFLMNF and Subtype of T Cell in Malignant Ascites and Hydrothorax Before and Post the Treatment of IL-2

Treatment of Malignant Serosal Effusion Through Injecting Donor Lymphocytes into Serosal Cavity

Clinical Reserch of Therapy Combined with Thermotherapy Plus Kanglaite and Cisplation in the Treatment of Malignant Pleural Effusion

The efficacy of rmhTNF combined with TC regimen as postoperative adjuvant therapy for non-small-cell lung cancer

Observation on Clinical Effects of Dendritic Cell Vaccines Combined with Cytokine-Induced Killer Cells Intraperitoneal Injection on Patients with Malignant Peritoneal Effusion

Observation of using microtrauma method with central venous catheter in the indwelling drainage and treatment for malignant pleural effusion by intrapleural injection drugs

Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion

[Treatment of Malignant Effusions with the Injection of Dendritic Cells Derived from Autologous Peripheral CD34+ Stem Cells].

Intracavitary infusion treatment of malignant effusion in body cavity with highly agglutinated staphytococcin plus cisplatin

Evaluating the effect of united treatment of malignancy pleural effusion with closed drainage with self- restraint 10F canal and injecting pleural cavity of medicine

Intracatheter Injection of IL-2 and DDP Combined with Closed Thoracic Drainage in Treatment of Malignant Pleural Effusion